The company has shown remarkable growth, posting a three-year CAGR of around 75% with an ARR of roughly Rs 100 crore and impressive gross margins
The LIFT-PD study will enroll 75 Parkinson’s patients experiencing apathy across 16 sites in Germany, Bulgaria, Poland and Spain
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
Brivaracetam Oral Solution (10 mg/mL) is a prescription antiepileptic drug (anticonvulsant) used for treatment of partial-onset seizures in patients 1 month of age and older
Brivaracetam is the bioequivalent to Briviact Oral Solution, 10 mg/mL, of UCB
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care
The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission
A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula
Alto met its enrollment goal with 83 patients across 13 US clinical sites
Subscribe To Our Newsletter & Stay Updated
